SIU Congress 2016: Is there a good risk muscle invasive bladder cancer? Neoadjuvant chemotherapy for all vs. for high risk only - Session Highlights


Buenos Aires, Argentina (UroToday.com) Juan Pablo Sade, Institute Alexander Fleming, Argentina, discussed risk stratification and selection of which patients should undergo neoadjuvant chemotherapy (NAC).


Aside from clinical predictors we have subtypes basal and luminal to predict which patients may benefit from NAC vs. upfront radical cystectomy. P-53 like tend to be refractory to chemotherapy whereas basal have clear sensitivity and luminal is somewhat sensitive to chemotherapy. Further research and clinical incorporation into the precision management of these patients are needed. Once again costs should be reduced in order to allow feasibility to incorporate precision medicine into everyday practice and optimize the survival and reduce morbidity of this disease.

World Urological Oncology Federation Symposium at the SIU Congress 2016 - October 20 - 23, 2016 – Buenos Aires, Argentina

Written By: Stephen B. Williams, M.D., Assistant Professor in Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish Kamat, M.D. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe